Ionis Pharmaceuticals slides as Wall Street digests HD program setback

Shares of Ionis Pharmaceuticals (IONS) are under pressure on Tuesday after the company announced that its partner Roche (RHHBY) decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen in manifest Huntington’s disease. While Cowen analyst… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3271425/-Ionis-Pharmaceuticals-slides-as-Wall-Street-digests-HD-program-setback)

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire